67 F. Supp. 3d 732
M.D. La.2014Background
- Boutte filed a Louisiana action against Stryker entities and Pisarello for injuries from OP-1 Putty and Calstrux; case removed to the Middle District of Louisiana on diversity grounds.
- Plaintiff alleges defective products, redhibitory defects, negligence, and fraud arising from off-label use of OP-1/Calstrux in Boutte’s 2006 surgeries.
- OP-1 Putty received FDA humanitarian device exemption; Calstrux approved as bone filler; the combination was never approved and was promoted off-label.
- Stryker allegedly learned of adverse effects but did not issue a Dear Doctor warning letter to avoid sales impact; Calstrux was later removed from the market (2009) after FDA action.
- Court analyzes claims under the Louisiana Products Liability Act (LPLA), noting its exclusive-liability framework, and considers redhibition as to economic losses.
- Defendant moved to dismiss under Rule 12(b)(6); Boutte desires discovery and expert input given the technical medical-device context.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Boutte states a viable design-defect claim under the LPLA | Boutte pled an alternative design and likelihood of damage | Boutte failed to allege an alternative design | Design-defect claim denied? actually denied? (court finds sufficient allegations at this stage) |
| Whether Boutte states an adequate warning claim under the LPLA | Mixture of OP-1 and Calstrux created new risk not fully warned | Existing warning on OP-1 does not cover the mixture | Warning claim denied or? court held sufficent factual matter to plausibly claim inadequate warning |
| Whether Boutte states a breach of express warranty claim under the LPLA | Defendant marketed the OP-1/Calstrux combination as safe and effective | No express warranty or misrepresentation asserted sufficiently | Breach of express warranty claim denied or allowed? court denied? actually held viable |
| Whether Boutte states a redhibition claim given the LPLA exclusivity for manufacturers | Redhibition preserved for economic-loss recovery | LPLA exclusive theories bar redhibition against manufacturers | Redhibition claim preserved and allowed to proceed at this stage |
| Whether negligence claim against Stryker Corporation is precluded by LPLA exclusivity | Corporation may be liable as parent for manufacturing actions | LPLA excludes parent liability or construction remains precluded | Negligence against Stryker Corporation not precluded at this stage |
Key Cases Cited
- Twombly, Bell Atl. Corp. v., 550 U.S. 544 (U.S. 2007) (plausibility pleading standard)
- Iqbal, Ashcroft v., 556 U.S. 662 (U.S. 2009) (fact-specific plausibility standard)
- Neitzke v. Williams, 490 U.S. 319 (U.S. 1989) (dismissal for invalid legal theories; early screening under Rule 12(b)(6))
- Pipitone v. Biomatrix, 288 F.3d 239 (5th Cir.2002) (LPLA redhibition and economic-loss considerations)
- Jefferson v. Lead Indus. Assoc., Inc., 106 F.3d 1245 (5th Cir.1997) (LPLA exclusive theories of liability for manufacturers)